Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 5/20 | 0.39 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.35 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | PDE9A | O76083 | 6/20 | 0.33 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.33 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3142967 | 0.91 | ALDH1A1 (0.41) | PARP1ALDH1A1ALOX15OPRL1 | |
| SCHEMBL3144768 | 0.84 | PARP1 (0.42) | PARP1PDCD1CD274PDE9APARP14 | |
| SCHEMBL3138115 | 0.84 | PARP1 (0.42) | PARP1PDCD1CD274PDE9APARP14 | |
| SCHEMBL3136154 | 0.83 | ALDH1A1 (0.41) | PARP1ALDH1A1ALOX15OPRL1GSK3B | |
| SCHEMBL3130337 | 0.74 | PARP1 (0.44) | PARP1ALDH1A1ALOX15GSK3BKCNH2 | |
| SCHEMBL3138956 | 0.74 | PARP1 (0.44) | PARP1ALDH1A1ALOX15GSK3BKCNH2 | |
| SCHEMBL3147409 | 0.73 | HTT (0.44) | PARP1PDE9AALDH1A1ALOX15GSK3B | |
| SCHEMBL2783035 | 0.73 | ALDH1A1 (0.40) | PARP1ALDH1A1ALOX15GSK3B | |
| SCHEMBL2801077 | 0.71 | ALDH1A1 (0.39) | PARP1ALDH1A1ALOX15 | |
| SCHEMBL3060533 | 0.71 | PARP1 (0.43) | PARP1ALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100121049-A1 | INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100004220-A1 | Indenoisoquinolinone Analogs and Methods of Use Thereof | INOTEK PHARMACEUTICALS CORPORATION | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121049-A1 | INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF | TNNI3, IDH2, GLS | PARP1 188/4885PDCD1 1171/4885CD274 2018/4885 |
| US-20100004220-A1 | Indenoisoquinolinone Analogs and Methods of Use Thereof | TNNI3, IDH2, GLS | PARP1 188/4885PDCD1 1171/4885CD274 2018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.